Combined therapy with pioglitazone and FGF21 mRNA synergistically ameliorates metabolic disorders in NAFLD rats

BACKGROUND: Current study aims to investigate the ameliorative effect of pioglitazone (PIO) combined with mRNA encoding FGF21 (termed mFGF21) on the metabolic disorders in rats with nonalcoholic fatty liver disease (NAFLD) and its potential mechanism. METHODS: In vitro functional activity of FGF21 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xixia, Xia, Zuyu, Huang, Yiqin, Sun, Yifei, Zhang, Lina, Xiong, Wenjian, Zhang, Ziyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133668/
https://www.ncbi.nlm.nih.gov/pubmed/37123911
http://dx.doi.org/10.1016/j.heliyon.2023.e15146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133668/
https://www.ncbi.nlm.nih.gov/pubmed/37123911
http://dx.doi.org/10.1016/j.heliyon.2023.e15146

Ejemplares similares